Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 133, Issue 18

May 2 2019

In this Issue

BLOOD COMMENTARIES
PLENARY PAPER
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
RED CELLS, IRON, AND ERYTHROPOIESIS
BLOOD WORK

BLOOD COMMENTARIES

Hematopoiesis and Stem Cells

Loss of hematopoietic diversity with age

Isabel Beerman

View Articletitled, Loss of hematopoietic diversity with age

CLINICAL TRIALS AND OBSERVATIONS

Venetoclax: R-CHOP rocket booster?
Clinical Trials & Observations

Charles Herbaux,Matthew S. Davids

View Articletitled, Venetoclax: R-CHOP rocket booster?

Red Cells, Iron, and Erythropoiesis

Blocking COX-2 for sickle cell pain relief

Katelyn E. Sadler,Cheryl L. Stucky

View Articletitled, Blocking COX-2 for sickle cell pain relief

PLENARY PAPER

Hematopoiesis and Stem Cells

The global clonal complexity of the murine blood system declines throughout life and after serial transplantation

Miguel Ganuza,Trent Hall,David Finkelstein,Yong-Dong Wang,Ashley Chabot,Guolian Kang,Wenjian Bi,Gang Wu,Shannon McKinney-Freeman

View Articletitled, The global clonal complexity of the murine blood system declines throughout life and after serial transplantation

Supplemental data

REVIEW ARTICLE

Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities

Marie-Dominique Filippi,Saghi Ghaffari

View Articletitled, Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities

CLINICAL TRIALS AND OBSERVATIONS

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Clinical Trials & Observations

Thierry Facon,Jae Hoon Lee,Philippe Moreau,Ruben Niesvizky,Meletios Dimopoulos,Roman Hajek,Ludek Pour,Artur Jurczyszyn,Lugui Qiu,Zandra Klippel,Anita Zahlten-Kumeli,Muhtarjan Osman,Bruno Paiva,Jesus San-Miguel

View Articletitled, Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Supplemental data

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Clinical Trials & Observations

Andrew D. Zelenetz,Gilles Salles,Kylie D. Mason,Carla Casulo,Steven Le Gouill,Laurie H. Sehn,Herve Tilly,Guillaume Cartron,Martine E. D. Chamuleau,Andre Goy,Constantine S. Tam,Pieternella J. Lugtenburg,Adam M. Petrich,Arijit Sinha,Divya Samineni,Sylvia Herter,Ellen Ingalla,Edith Szafer-Glusman,Christian Klein,Deepak Sampath,Martin Kornacker,Mehrdad Mobasher,Franck Morschhauser

View Articletitled, Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects

Amy P. Hsu,Agnes Donkó,Megan E. Arrington,Muthulekha Swamydas,Danielle Fink,Arundhoti Das,Omar Escobedo,Vincent Bonagura,Paul Szabolcs,Harry N. Steinberg,Jenna Bergerson,Amanda Skoskiewicz,Melanie Makhija,Joie Davis,Ladan Foruraghi,Cindy Palmer,Ramsay L. Fuleihan,Joseph A. Church,Avinash Bhandoola,Michail S. Lionakis,Sharon Campbell,Thomas L. Leto,Douglas B. Kuhns,Steven M. Holland

View Articletitled, Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Sensitization of nociceptors by prostaglandin E₂–glycerol contributes to hyperalgesia in mice with sickle cell disease

Iryna A. Khasabova,Megan Uhelski,Sergey G. Khasabov,Kalpna Gupta,Virginia S. Seybold,Donald A. Simone

View Articletitled, Sensitization of nociceptors by prostaglandin E<sub>2</sub>–glycerol contributes to hyperalgesia in mice with sickle cell disease

BLOOD WORK

Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production

M. V. E. Andriessen,R. Raymakers

View Articletitled, Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production

Cover Image

Cover Image

COS-7 cells transfected with wild-type RAC2 and green fluorescent protein expression vectors. Staining of RAC2 (red) and F-actin (orange) shows a nascent phagocytic cup with high levels of RAC2 protein (cell on right). Unlike mutant RAC2[E62K], overexpression of normal RAC2[wild-type] does not affect actin formation. See the article by Hsu et al on page 1977.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Licking the wound with procoagulant vesicles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

CAR T-cells in autoimmunity: game changer or stepping stone?

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Table of Contents

BLOOD COMMENTARIES

Loss of hematopoietic diversity with age

Venetoclax: R-CHOP rocket booster?
Clinical Trials & Observations

Blocking COX-2 for sickle cell pain relief

PLENARY PAPER

The global clonal complexity of the murine blood system declines throughout life and after serial transplantation

REVIEW ARTICLE

Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities

CLINICAL TRIALS AND OBSERVATIONS

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Clinical Trials & Observations

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects

RED CELLS, IRON, AND ERYTHROPOIESIS

Sensitization of nociceptors by prostaglandin E₂–glycerol contributes to hyperalgesia in mice with sickle cell disease

BLOOD WORK

Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD COMMENTARIES

Loss of hematopoietic diversity with age

Venetoclax: R-CHOP rocket booster? Clinical Trials & Observations

Blocking COX-2 for sickle cell pain relief

PLENARY PAPER

The global clonal complexity of the murine blood system declines throughout life and after serial transplantation

REVIEW ARTICLE

Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities

CLINICAL TRIALS AND OBSERVATIONS

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma Clinical Trials & Observations

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects

RED CELLS, IRON, AND ERYTHROPOIESIS

Sensitization of nociceptors by prostaglandin E2–glycerol contributes to hyperalgesia in mice with sickle cell disease

BLOOD WORK

Neutrophilic leukemoid reaction with extended fibrosis due to ectopic G-CSF production

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Venetoclax: R-CHOP rocket booster?
Clinical Trials & Observations

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Clinical Trials & Observations

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Clinical Trials & Observations

Sensitization of nociceptors by prostaglandin E₂–glycerol contributes to hyperalgesia in mice with sickle cell disease